CRBN and cancer: What's more, cancer cells with high CRBN expression exhibited marked sensitivity to GSPT1 MGDs compared to other cancer types.[115, 163] However, the challenges of GSPT1 MGDs clinical trials may imply that targeting different E3 ligases will promote the development of more potent GSPT1 MGDs by enhancing degradation efficiency and overcoming potential resistance mechanisms.